No significant association seen for increased risk for MCMs with metformin in monotherapy, but association suggested for metformin in polytherapy
By Elana Gotkine HealthDay Reporter
MONDAY, June 17, 2024 (HealthDay News) — Paternal use of metformin in monotherapy is not associated with an increased risk for major congenital malformations (MCMs), according to a study published online June 18 in the Annals of Internal Medicine.
Ran S. Rotem, Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the association between paternal metformin use during spermatogenesis and MCMs in newborns to assess the potential adverse intergenerational effect of metformin in a nationally representative cohort study. Data were included for 383,851 live births that occurred in 1999 to 2020.
The researchers found that the prevalence of cardiometabolic morbidity was substantially higher among fathers who used metformin during spermatogenesis and their spouses compared with unexposed fathers. The crude odds ratio for paternal metformin exposure in all formulations and MCMs was 1.28 (95 percent confidence interval, 1.01 to 1.64), but the odds ratio after adjustment was 1.00 (95 percent confidence interval, 0.76 to 1.31). The adjusted odds ratio was 0.86 (95 percent confidence interval, 0.60 to 1.23) and 1.36 (95 percent confidence interval, 1.00 to 1.85) for metformin in monotherapy and for metformin in polytherapy, respectively.
“Future research should examine the intergenerational effects of paternal cardiometabolic morbidity and related drug treatments while applying specific focus to polytherapies and aiming to disentangle potential drug-related effects from effects exerted by the underlying clinical indication,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
